Latest news

Thumbnail image for Sanofi, Alnylam file hATTR amyloidosis therapy in the EU

Sanofi, Alnylam file hATTR amyloidosis therapy in the EU

Sanofi Genzyme and Alnylam Pharmaceuticals have submitted a marketing application to the European Medicines Agency for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis.

20th December 2017

Thumbnail image for Takeda’s Ninlaro approved for NHS use via CDF

Takeda’s Ninlaro approved for NHS use via CDF

Patients in England and Wales will now be able to access Takeda’s myeloma treatment Ninlaro on the NHS, after cost regulators cleared its use through the Cancer Drugs Fund (CDF).

20th December 2017

Thumbnail image for NICE turns down rare skin disease implant

NICE turns down rare skin disease implant

The National Institute for Health and Care Excellence has rejected Clinuvel UK’s afamelanotide for treating erythropoietic protoporphyria (EPP) in preliminary guidelines deeming it far too expensive for NHS use.

20th December 2017

Thumbnail image for Teva’s anti-CGRP drug under review for migraine

Teva’s anti-CGRP drug under review for migraine

US regulators are now reviewing Teva Pharmaceutical’s experimental anti-CGRP therapy fremanezumab for the preventive treatment of migraine, and have also granted the drug a fast track designation for the prevention of cluster headache.

19th December 2017

Thumbnail image for US priority review for AZ’ Tagrisso

US priority review for AZ’ Tagrisso

US regulators are undertaking a speedy review of AstraZeneca's application to market Tagrisso as first-line treatment for lung cancer.

18th December 2017

Thumbnail image for Horizon expands agreement with Roche Diagnostics

Horizon expands agreement with Roche Diagnostics

Cambridge, UK-based Horizon Discovery has expanded its relationship with Roche Diagnostics with a new agreement to assist in the development of immunohistochemistry (IHC) assays.

18th December 2017

Thumbnail image for Pfizer’s Xeljanz wins US nod for psoriatic arthritis

Pfizer’s Xeljanz wins US nod for psoriatic arthritis

Pfizer Xeljanz and Xeljanz XR have received US marketing clearance for the treatment of adults with active psoriatic arthritis who have failed to respond or are intolerant to methotrexate or other disease-modifying antirheumatic drugs.

18th December 2017

Thumbnail image for Seven therapies backed for EU approval

Seven therapies backed for EU approval

Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.

18th December 2017

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download